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The aims of this study were to compare the automated AxSYM avidity assay index with
the  BED capture enzyme immunoassay test and to calculate the HIV-1 incidence using the
BED  capture enzyme immunoassay and AxSYM avidity assay index algorithms within a
population seeking the Voluntary Counselling and Testing Centres in two municipalities
in  the Metropolitan Region of Recife, Northeast of Brazil. An analysis was conducted in 365
samples that tested positive for HIV infection from frozen serum collected during the period
2006–2009. There was a similar proportion of males and females; most patients were hetero-
sexual (86%) with a median age of 29 years. Of the 365 samples, 102 (28%) and 66 (18.1%) were
identiﬁed as recent infections by BED capture enzyme immunoassay and AxSYM avidity
assay index, respectively. The HIV-1 total incidence in the BED capture enzyme immunoas-
say and AxSYM avidity assay index algorithms were: 0.79 (95% CI: 0.60–0.98) and 0.34 (95%
CI:  −0.04 to 0.72), respectively. Incidence was higher among men. There was good agree-
ment between the tests, with a kappa of 0.654 and a speciﬁcity of 95.8%. AxSYM avidity
assay index may be helpful in improving the quality of the estimates of recent HIV infectionand  incidence, particularl
immunoassay.
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Brazil has reported 656,701 cases of AIDS, and in recent
years there has been an increase in the rate of cases in the
North and Northeast regions of the country, when compared
to the South and Southeast regions. Furthermore, the North-
eastern state of Pernambuco and its capital Recife present the
highest rates of new cases of AIDS of any state or state capital
in Northeast Brazil.1
The growing interest in estimating HIV-1 incidence has led
to the development of a variety of laboratory assays. This
methodology is used only for epidemiological investigation
purposes, and is referred to by the recently introduced term
RITA (Recent Infection Testing Algorithm), used to describe
laboratory assays that are able to identify a transitional period
of recent seroconversion of HIV infection.2
In 1998, an adaptation of a diagnostic test for HIV-1
that would revolutionize epidemiological methods through
its ability to identify recent HIV-1 infection was described in
the literature.3 The test differentiated recent infections (less
than six months) from established infections (more than six
months), due to the kinetics of antibodies after the onset of
HIV-1 infection. This test allowed to estimate HIV-1 incidence
from cross-sectional studies, using a single serum sample per
patient.
The BED capture enzyme immunoassay (BED-CEIA), the
assay for HIV-1 incidence, has peptides as antigens derived
from the immunodominant region of gp41, containing
sequences of subtypes B, E and D, which are representative of
multiple subtypes of HIV-1. The time at which HIV infection
occurred can be estimated, given that the ratio between the
total IgG and anti-HIV IgG varies according to the progression
of the disease.4 This technique has been widely used in con-
junction with mathematical tools for estimating the incidence
of HIV infection.5
Another method for distinguishing between recent and
established HIV infections based on antibody avidity (afﬁnity)
was described in 2002.6 This methodology is based on the prin-
ciple that the antibody avidity produced in the initial phase of
the infection (within six months of seroconversion) is low, in
contrast to that observed in established infections (more than
six months).6 Besides the simplicity and automated nature of
the technique, in theory, it would also be able to detect a high
proportion of subtypes of HIV-1 and would not be affected by
the stage of the infection. The association of the two tests has
been used to conﬁrm the positive results of BED, resembling
results of incidence data of cohorts that have documented
seroconversion.7
In view of the importance of comprehending the dynamics
of the HIV epidemic, the aim of this study were to compare the
magnitude of agreement between the automated test AxSYM
avidity assay index (Ax-AI) with the BED-CEIA test and to
calculate the HIV-1 incidence using BED and Ax-AI within a
population seeking Voluntary Counselling and Testing Cen-
tres (VCTs) in two municipalities of the Metropolitan Region
of Recife, in Northeast Brazil.
Frozen samples from patients diagnosed with HIV infec-
tion during the period 2006–2009 were obtained from two
VCTs in the municipalities of Cabo de Santo Agostinho and
Paulista, in the Metropolitan Region of Recife – Northeast
Brazil. Three hundred and eighteen patients were diagnosed
as HIV-infected at the VCT in Cabo de Santo Agostinho, and 1 4;1  8(4):449–453
aliquots from 206 (64.8%) of them were available for further
testing. At the Paulista VCT, 179 cases of HIV infection were
detected, but only 159 (94%) had serum available for testing.
Thus a total of 365 serum samples were analyzed.
Samples from patients with previous use of antiretrovi-
ral therapy (ART), infected through vertical transmission, and
those with previous diagnosis of HIV infection occurring more
than six months prior to the collection of the sample were
excluded.
Data relating to the individuals’ gender, age, and sociode-
mographic data were retrieved from the databank of the HIV
test result information system (SIREX-HIV) at the VCTs. This
study was approved by the Research Ethics Committee of the
Hospital Agamenon Magalhães (protocol number 518/2009).
For the Ax-AI the sample was defrosted, two aliquots of
20 L were obtained and diluted 1:10. One aliquot (PBS aliquot)
was diluted with 180 L of phosphate-buffered saline (PBS) and
the other (G aliquot) was diluted with 180 L of 1 M guanidine
solution (G) (Sigma–Aldrich). After dilution, all samples were
vortex-stirred and incubated for 10 min  at room temperature.
The two aliquots of each sample were tested using the auto-
mated AxSYM HIV-1/2 gO assay (Abbott Diagnostics Division,
Wiesbaden-Delkenheiem, Germany), in accordance with the
manufacturer’s instructions.6
Addition of a denaturing agent (guanidine) breaks hydro-
gen bridges, which helps determining the secondary structure
of the antibodies and leads to a residual effect from the
antigen–antibody interaction. This procedure has greater
effect on recent antibodies, which are low-avidity antibodies.8
This procedure results in an S/CO ratio that is lower for the G
aliquot than for the PBS aliquot. The avidity index (AI) is calcu-
lated after obtaining the S/CO ratios for the PBS and G aliquots
as follows:6,9
AI = Guanidine aliquot S/CO
PBS aliquot S/CO
.
A cutoff value of 0.8 distinguishes an infection of less than
six months6,10 from a long-term infection (a duration of more
than six months).
The BED-CEIA test (Calypte Biomedical Corporation, Ore-
gon, USA) is an IgG-capture ELISA technique based on
detecting increasing proportions of speciﬁc anti-HIV-1 IgG fol-
lowing seroconversion. Anti-HIV IgG and non-speciﬁc IgGs are
captured in the solid phase of the microplate. After incuba-
tion and washing, peptides from the immunodominant region
of gp41 that contain sequences of the subtypes B, E and D
were added. After further incubation and washing, a strepta-
vidin conjugate was added, followed by an incubation period
of 90 min. The response is ascertained after the addition of
tetramethylbenzidine (TMB) with a spectrophotometer (wave-
length 450 nm).4,11
Following the immunoassays and reading of the spec-
trophotometer, the normalized optical densities (ODns) were
obtained, as follows:ODn of the sample = OD of the sample
median OD of the calibrator
.
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Table 1 – Demographics and behavioural data of patients
newly  diagnosed as HIV-positive at two VCTs in
Pernambuco – Brazil, 2006–2009.
Variables HIV-positive patients
Gender
Male 177 (48.5)
Female 188 (51.5)
Pregnant
Yes 53 (28.2)
No 135 (71.8)
Median age (years) 29
Sexual orientation
Heterosexual 304 (86)
MSMa 50 (14)
Risk situationb
Blood transfusion 14
Sex worker 08
HIV+ partner 26
Schooling
≤8 years 231 (63.3)
>8 years 123 (33.7)
Not informed 11 (3.0)
Employment situation
Employed 69 (18.9)
Self-employed 42 (11.5)
Unemployed 61 (16.7)
Student 25 (6.8)
Housewife 117 (32.1)
Retired 09 (2.5)
Not informed 42 (11.5)
a MSM, men who have sex with men.
b Not expressed in percentage since most patients did not presentb r a z j i n f e c t d i s .
The tests were interpreted as follows: all samples with
Dn ≤ 1.2 were tested in triplicate to conﬁrm whether it
as a recent or long-term infection. Conﬁrmation inter-
retation: samples with OD > 0.8 were characterized as
ong-term seroconversion and those with OD ≤ 0.8 as recent
eroconversion.12
HIV-1 incidence and 95% conﬁdence interval (95% CI)
or the BED-CEIA and Ax-AI algorithms were calculated
sing the spreadsheet provided by the South African Cen-
re for Epidemiological Modelling and Analysis (SACEMA)
http://www.incidence-estimation.com/page/tools-for-inciden
he following parameters were reported on the spreadsheet:
he Estimated Mean Duration of Recent Infection (MDRI),
hich was 180 days for the Ax-AI and 155 days for the BED-
EIA;4 the estimated False Recent Rate (FRR%), which was
.6%,14 and 10.6% for the BED-CEIA and Ax-AI, respectively;7,14
umber of HIV-positive individuals; number of HIV-negative
ndividuals and number of recent HIV-1 infections. Inci-
ence estimates were expressed as the number of new HIV
nfections per 100 person-years.
Sensitivity, speciﬁcity, positive and negative predictive val-
es, accuracy, likelihood ratios for positive and negative tests,
nd kappa were obtained by comparing the results of Ax-AI
o those of BED-CEIA, using the MSOfﬁce Excel version 2010
Microsoft Corporation) and the SPSS for Windows version
2.0. Signiﬁcant associations between the variables were con-
idered when p-values were less than 0.5.
The study population consisted of 177 men  (48.5%) and
88 women (51.5%), of whom 53 (28.2%) were pregnant. The
edian age was 29 years. Other epidemiologic and behaviour
ata are listed in Table 1. Ax-AI and BED-CEIA results were
ompared using 365 samples. One hundred and two sam-
les were identiﬁed as recent infection by BED-CEIA, and 77
amples by Ax-AI. For the status of long-term infection, the
ED-CEIA and Ax-AI identiﬁed 263 and 288 samples, respec-
ively. Both tests were concordant in 66 samples classiﬁed as
ecent infection and 252 as a long-term infection.
When compared to the BED-CEIA, with a cutoff of 0.8, the
x-AI showed 64.7% sensitivity of and 95.8% speciﬁcity, with
ates of positive predictive values (PPV) and negative (NVP)
reater than 85%. The agreement beyond chance between the
wo techniques was good (kappa = 0.654, p < 0.001).
BED-CEIA and Ax-AI results for six patients whose sero-
onversion date was equal to or less than a year, conﬁrmed by
 negative assay for HIV followed by a positive assay within
2 months, demonstrated disagreement in only two patients
he classiﬁcation status of recent infection. In one of these
ases seroconverted after seven months and BED-CEIA ODn
as borderline (at the cutoff threshold) (data not shown).
Global HIV-1 incidences according to BED-CEIA and Ax-AI
ere 0.79 (95% CI: 0.60–0.98) and 0.34 (95% CI: 0–0.72), respec-
ively. Thus, the incidence rate estimated by the BED-CEIA
as signiﬁcantly higher (p > 0.0001). The number of recent
nfections among HIV positive individuals, for the BED-CEIA,
x-AI and BED + Ax-AI were 105, 77 and 66 (p = 0.004). Only
he Ax-AI demonstrated a signiﬁcant increasing tendency of
IV incidence with time (p = 0.02). The incidence estimates
aried between 0.66 and 0.97%/year and 0.19 and 0.45%/year
or the BED-CEIA and Ax-AI, respectively. All methods for
stimating HIV-1 incidence showed signiﬁcantly higher ratesthis risk.
for men  than for women (p < 0.0001), with a difference of
approximately threefold (Table 2).
The present study demonstrates that estimates of HIV
incidence in a population seeking VCTs in two municipali-
ties within the Metropolitan Region of Recife, capital city of
Pernambuco, Northeast Brazil, may vary according to the diag-
nostic algorithm used, with a rate of 0.79%/year when using
the BED and 0.34%/year with the Ax-AI, excluding those on
HAART. The BED-CEIA methodology has been widely used
to measure the incidence of HIV-1 in cross-sectional stud-
ies, mainly due to its commercial availability. However, many
questions remain regarding its accuracy, with a suggestion
of overestimation, despite the consensual use of correction
factors.2 The WHO  Working Group on HIV  Incidence Assays
systematically reviewed the accuracy of serological tests for
recent infections with HIV. Across 13 different assays, sen-
sitivity to detect recent infections ranged from 42 to 100%
(median 89%). Speciﬁcity for detecting established infections
was between 49.5 and 100% (median 86.8%) and was higher
for infections of durations longer than one year (median 98%,
range 31.5–100.0). Serological assays have reasonable sensi-
tivity for detecting recent HIV infection, but are vulnerable
to misclassifying established infections as recent, potentially
leading to biases in incidence estimates.15 The use of a multi-
assay algorithm has been suggested, in which BED-CEIA in
452  b r a z j i n f e c t d i s . 2 0 1 4;1  8(4):449–453
Table 2 – Annual HIV-1 incidence estimated by using the BED-CEIA, Ax-AI, and BED-CEIA + Ax-AI algorithms.
Year/gender No. of individuals No. of individuals Incidence BED
(%) – (95% CI)d
Incidence Ax-AI
(%) – (95% CI)d
HIV positivea
(BED samples)b
(Ax-AI samples)c
HIV negative Recent
infection
(BED)
Recent
infection
(Ax-AI)
Recent
infection
(BED  + Ax-AI)
2006 111a (66)b (64)c 8931 18 11 09 0.70 (0.38–1.02) 0.19 (0–0.63)
2007 141 (98) (90) 9242 29 20 16 0.97 (0.60–1.35) 0.45 (0–0.94)
2008 122 (118) (118) 9208 34 26 24 0.81 (0.47–1.14) 0.38 (0–0.81)
2009 123 (93) (93) 9998 24 20 17 0.66 (0.36–0.95) 0.34 (0–0.74)
Male 243 (180) (177) 8449 44 37 32 1.46 (0.94–1.97) 0.77 (0–1.65)
Female 254 (195) (188) 28,930 61 40 34 0.59 (0.42–0.76) 0.24 (0–0.51)
Total 497 (375) (365) 37,379 105 77 66 0.79 (0.60–0.98) 0.34 (0–0.72)
a A total of 10 HIV-positive patients were excluded from the incidence calculation: eight had presented a previous positive serological test
for HIV, one was vertical transmission, and another was undergoing antiretroviral treatment. Three of these individuals were from the 2006
cohort, two were from the 2007 cohort, three were from the 2008 cohort, and two from the 2009 cohort.
b Total number of available aliquots for BED-CEIA testing.
rc Total number of available aliquots for Ax-AI testing.
d Results are expressed as the incidence/100 people/year (95% CI).
combination with an avidity assay was cited as the most com-
monly used algorithm.2
The present study tested this strategy in individuals in
the metropolitan area of Recife, Northeast Brazil, where the
most prevalent subtypes B are (around 57%), F (around 37.7%)
and C (around 3.1%).16 A signiﬁcant difference was observed
between incidence rates estimated by BED-CEIA (0.79%/year)
and Ax-AI (0.34%/year) (p < 0.00001).
One major difﬁculty when discussing estimates of HIV
incidence is the difference among populations studied. Most
studies have a target population of groups at risk, especially
sex workers, men  who have sex with men  (MSM) and injected
drug users. This research evaluated a mixed population from
two VCTs in the Brazilian state of Pernambuco, which were
linked to the Brazilian Ministry of Health’s National STD and
AIDS Programme. In this region, those attending the VCTs con-
sist of three main groups: people from the general community,
usually of low risk infection, pregnant women from within the
community, and individuals with behaviour patterns associ-
ated with an increased risk of infection (e.g. sex workers and
MSM).  Thus, one limitation of this study among other studies
in Brazil is the heterogeneity of the population studied plus the
fact that the accuracy of the estimates of incidence by sero-
logical methods depends on the accuracy of the mean RITA
duration and the RITA FRR, which are the measures evaluated
for populations with characteristics different from those of the
present study.17
There are data illustrating that the avidity test presents a
better performance in correctly classifying individuals with
a long-term viral load, while the BED-CEIA has greater ten-
dency to classify them erroneously as recent infections.18
Furthermore, it has been shown that AI-Ax suffers less inter-
ference from the HIV subtype and antibody titres in their
performance.6
The incidence estimates presented herein were about
threefold higher for men  than for women. The Brazilian epi-
demic is concentrated within certain groups, especially young
MSM.1 However in the present study, this group accounted
for only 14%, thus, underrepresented in the population ofVCTs studied. In Brazil, there have been several studies, which
applied serological methods to estimate HIV-1 incidence,
especially in the South and Southeast. Although a consid-
erable portion of these studies included individuals with a
higher risk for HIV infection, such as prisoners, cocaine and
injected drugs users, MSM and high-risk heterosexual men
and women, incidence data for both sexes show a higher rate
for men, as observed by Schechter et al.19 and Alves et al.,20
where the estimated incidence rate was between 1.9 and 2%
for women and 2.8 and 2.7% for men  and, respectively.
Given the large number of diagnostic tests performed for
HIV infection (132 million/year) and blood bank screening (101
million/year), as well as recognizing the huge market involved,
the importance of applying the RITA methodology should be
emphasized in order to provide a better map  of the spread
of the epidemic and allow adequate structuring of preventive
strategies. To our knowledge, this is the ﬁrst study in Brazil
to apply the concept of the dual testing algorithm to deter-
mine estimates of HIV incidence, based on the most recent
recommendations of the WHO.2,14
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